Seamus Fernandez
Stock Analyst at Guggenheim
(4.93)
# 33
Out of 5,124 analysts
119
Total ratings
69.41%
Success rate
69.37%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TENX Tenax Therapeutics | Maintains: Buy | $14 → $25 | $13.27 | +88.39% | 3 | Dec 17, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $120 → $140 | $99.42 | +40.82% | 3 | Dec 17, 2025 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Buy | $62 | $54.42 | +13.93% | 13 | Dec 12, 2025 | |
| SNY Sanofi | Downgrades: Neutral | n/a | $48.17 | - | 1 | Dec 9, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,036 → $1,163 | $1,064.04 | +9.30% | 22 | Dec 3, 2025 | |
| IVA Inventiva | Maintains: Buy | $13 → $11 | $4.54 | +142.29% | 1 | Nov 18, 2025 | |
| CDTX Cidara Therapeutics | Downgrades: Neutral | n/a | $221.38 | - | 6 | Nov 18, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $84 → $77 | $28.70 | +168.29% | 4 | Nov 10, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Downgrades: Neutral | n/a | $6.61 | - | 4 | Oct 23, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $17 → $25 | $11.38 | +119.68% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $63.24 | +42.31% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $116 | $78.25 | +48.24% | 8 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $29.22 | - | 3 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $44.85 | +256.74% | 4 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $35.71 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $108.87 | +12.06% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $50.56 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.96 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $56.26 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $142.27 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.22 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $2.65 | +1,937.74% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $26.28 | +71.23% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $94.96 | -59.98% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $25.43 | +49.43% | 3 | Jan 31, 2018 |
Tenax Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $14 → $25
Current: $13.27
Upside: +88.39%
Rhythm Pharmaceuticals
Dec 17, 2025
Maintains: Buy
Price Target: $120 → $140
Current: $99.42
Upside: +40.82%
Bristol-Myers Squibb Company
Dec 12, 2025
Upgrades: Buy
Price Target: $62
Current: $54.42
Upside: +13.93%
Sanofi
Dec 9, 2025
Downgrades: Neutral
Price Target: n/a
Current: $48.17
Upside: -
Eli Lilly and Company
Dec 3, 2025
Maintains: Buy
Price Target: $1,036 → $1,163
Current: $1,064.04
Upside: +9.30%
Inventiva
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $4.54
Upside: +142.29%
Cidara Therapeutics
Nov 18, 2025
Downgrades: Neutral
Price Target: n/a
Current: $221.38
Upside: -
MBX Biosciences
Nov 10, 2025
Maintains: Buy
Price Target: $84 → $77
Current: $28.70
Upside: +168.29%
Arcturus Therapeutics Holdings
Oct 23, 2025
Downgrades: Neutral
Price Target: n/a
Current: $6.61
Upside: -
Amylyx Pharmaceuticals
Sep 15, 2025
Maintains: Buy
Price Target: $17 → $25
Current: $11.38
Upside: +119.68%
Aug 7, 2025
Maintains: Buy
Price Target: $92 → $90
Current: $63.24
Upside: +42.31%
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $78.25
Upside: +48.24%
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $29.22
Upside: -
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $44.85
Upside: +256.74%
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $35.71
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $108.87
Upside: +12.06%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $50.56
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.96
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $56.26
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $142.27
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.22
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $2.65
Upside: +1,937.74%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $26.28
Upside: +71.23%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $94.96
Upside: -59.98%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $25.43
Upside: +49.43%